Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- PI3K/Akt signal transduction pathway
- PI3K signaling - the big picture
- Mutations in the signaling pathway in cancer (1)
- Mutations in the signaling pathway in cancer (2)
- Inhibitors of PI3K-AKT signaling in development
- Key concepts
- Oncogene addiction/genetic dependency
- AKT1/2 inhibitor (AKTi-1/2)
- Breast cancer
- AKT inhibition in mutated cell lines
- AKTi-1/2 in PI3K mutatant vs. wt cancer cells
- AKTi causes G1 arrest and induces apoptosis
- AKTi effectively inhibits AKT signaling in vivo
- HER2-overexpressing cells retain AKT dependence
- AKT inhibition affects glucose levels
- Mutated elements in tumors
- AKTi sensitivity in cells with various mutations
- Loss of K-Ras mutation in PIK3CA mutant cells
- Different genes are mutated in the same cancer
- Integrators of multiple signaling pathways
- BAD as an integrating protein
- 4EBP1 as an integrating protein
- 4EBP1 is an integrator of PI3K and RAS signaling
- 4EBP1 knockdown affects translation
- 4EBP1 knockdown affects apoptosis
- PTEN expression synergizes with EGFR inhibition
- Questions
- AKTi synergizes with MEK inhibition
- Combined effects of AKT and ERK inhibition
- Feedback inhibition of insulin/IGF-1 signaling
- Rapamycin feedback on P-AKT but not P-S6K
- mTOR inhibition activates AKT in patients
- The concept of feedback
- Clinical effects of Rapamycin-like drugs
- mTORC1 mediated feedback on IRS-1
- AKT inhibition effects on tyrosine kinases
- mTOR inhibition leads to PI3K activation
- mTOR inhibition effects in vivo
- Model: mTOR vs. AKT regulated feedback
- Combining AKT and HER/EGFR inhibition
- Combining AKT and HSP90 inhibition
- Clinical uses of AKT inhibitors
- Summary
- Acknowledgments
Topics Covered
- PI3K/AKT signal transduction pathway
- Tumors with frequent dysregulation of PI3K signalling
- Modalities for inhibiting PI3K-AKT signaling currently in development
- AKT1/2 inhibitor (Merck)
- PI3K/AKT in breast cancer
- AKTi-1/2 inhibits AKT signaling and causes G1 arrest
- The Herceptin-resistant
- Effect of AKT inhibition on glucose levels
- Mutated elements in mitogenic signaling pathways in tumors
- Coexistent K-Ras or B-Raf mutation
- Genes encoding several components of mitogenic signaling pathways are mutationally activated in tumors
- Integrators of multiple signaling pathways (OR-gates)
- The effects of combined inhibition of AKT and MAPK on the phosphorylation of translational regulatory proteins
- Knockdown of 4EBP1 expression
- Feedback inhibition of insulin/IGF-1 signaling
- The concept of feedback
- Clinical effects of Rapamycin-like drugs
- mTORC1 vs. AKT regulated feedback
- Clinical uses of AKT inhibitors
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Rosen, N. (2011, December 5). PI3K/AKT signaling in cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/KLNQ5002.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Neal Rosen has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Oncology
Transcript
Please wait while the transcript is being prepared...
0:00
I am speaking today about the PI3K signaling pathway in cancer.
This is one of the most commonly activated and mutated pathways in cancer,
and we believe it plays an important role in the development of cancer and offers us
the opportunity to develop drugs
that inhibit this pathway, ought to be very useful in treatments.
0:25
PI3 kinase is an important signaling pathway in normal physiology.
It regulates metabolism, cell growth,
cell migration, and cell survival.
One of its key functions is regulation of metabolism and glucose homeostasis
because it's the most important downstream effector pathway that
is activated by the insulin and IGF-1 molecules.
The way this works is insulin or IGF-1 bind to a receptor,
either the insulin receptor or IGF-1 receptor,
and this causes the activation of the receptor.
The activated receptor phosphorylates
a whole variety of substrates including the IRS molecules.
Phosphorylation of these molecules causes their recruitment
to an activation of a variety of intracellular signaling molecules.
For the purpose of this talk,
the most important one of these is PI3 kinase.
PI3 kinase is an enzyme that consists of two sub-units,
a regulatory sub-unit which in this case is an 85 kilodalton sub-unit,
and a catalytic subunit, 110 kilodaltons.
This is a big family,
but these are the most commonly studied,
the class 1 kinases.
What this enzyme does is it phosphorylates phosphatidylinositol
on the three position which causes the formation of PIP3.
PIP3, which becomes phosphorylated in other positions,
the four and five position,
binds to a whole variety of proteins in the cell that have PH domains.
It binds to the phosphorylated phosphatidylinositol, PIP3, 4 or 5,
and causes it to dock to the plasma membrane
where it becomes activated by phosphorylation.
There are many such targets of
the phosphorylated phosphatidylinositols but the one that is
most well defined and most known to be important in cancer is the Akt kinase.
Akt kinase gets activated by phosphorylation after it binds to the membrane.
Phosphorylation on a serine at 473 and a threonine at 308, and Akt then
becomes activated and phosphorylates a whole variety
of substrates that are important in preventing cell death,
inducing cell growth, regulating metabolism, and inducing translation.
This whole pathway is down-regulated by a variety of
negative regulatory mechanisms including the PTEN protein.
The PTEN protein is a phosphatase that
de-phosphorylates the phosphatidylinositolphosphates on the three position,
thus turning off the pathway.
In the cell, the PI3 kinase pathway is regulated by